Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NV-001 in Advanced Solid Tumors
NCT06051760Phase 1Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2023
- Primary completion
- Mar 2025
- Modality
- Mesenchymal Stem Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NV-001 in solid tumor (advanced stage), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Dose-Limiting Toxicities at 28 days and Adverse Events at 36 months. Started Dec 2023; status: recruiting.
02
Drugs
NV-001
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06051760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06051760.